{
    "clinical_study": {
        "@rank": "122523", 
        "arm_group": [
            {
                "arm_group_label": "Levoleucovorin 200 mg/m2", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Levoleucovorin 60 mg/m2", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "6R-MTHF 200 mg/m2", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "6R-MTHF 60 mg/m2", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the concentration of [6R] 5,10-methylene-THF,\n      5-formyl-THF, 5-methyl-THF and THF in the tumor, in adjacent mucosa and in plasma in\n      patients with colon cancer receiving two different does of  Modufolin\u00ae and Levoleucovorin\n      (Isovorin\u00ae) respectively (60 and 200 mg/m2)."
        }, 
        "brief_title": "PK/PD Investigation of Modufolin\u00ae in Plasma, Tumor and Adjacent Mucosa in Patients With Colon Cancer", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Colonic Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Colonic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients must have operable colon cancer that is amenable to curative   surgery.\n\n          2. Performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG).\n\n          3. Patients without contra indications for undergoing surgery.\n\n          4. For women: Must be surgically sterile, postmenopausal, or compliant with a\n             contraceptive regimen during and for 3 months after treatment; must have a negative\n             serum or urine pregnancy test (within 7 days before enrolment) and must not be\n             lactating.\n\n          5. For men: Must be surgically sterile or compliant with a contraceptive regimen during\n             and for 3 months after treatment.\n\n          6. Patients must sign an informed consent document.\n\n          7. Patient legally competent and able to communicate effectively with the study\n             personnel as judged by the investigator.\n\n          8. Patient likely to co-operate during the study.\n\n          9. Patients must be at least 18 years of age.\n\n        Exclusion Criteria:\n\n          1. Concurrent administration of any other anti-tumor therapy.\n\n          2. Treatment within the last 30 days with a drug/device that has not received regulatory\n             approval for any indication at the time of study entry.\n\n          3. Any intake of medication which could influence homocysteine, folate, and vitamin B12\n             status, within 30 days of surgery\n\n          4. Serious concomitant systemic disorders (e.g., active infection including HIV, cardiac\n             disease) that in the opinion of the investigator would compromise the patient's\n             ability to complete the study.\n\n          5. Are pregnant or breast-feeding.\n\n          6. Second primary malignancy that is clinically detectable at the time of consideration\n             for study enrollment.\n\n          7. History of significant neurological or mental disorder, including seizures or\n             dementia.\n\n          8. Presence of clinically relevant (i.e., detectable by physical examination)\n             third-space fluid collection (e.g., ascites, pleural effusion) that cannot be\n             controlled by drainage or other procedures prior to study entry.\n\n          9. Inability or unwillingness to be given Modufolin\u00ae or Levoleucovorin (Isovorin\u00ae)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01681472", 
            "org_study_id": "ISO-CC-002", 
            "secondary_id": "2012-000522-22"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "6R-MTHF 200 mg/m2", 
                    "6R-MTHF 60 mg/m2"
                ], 
                "description": "i.v. bolus injection", 
                "intervention_name": "[6R] 5,10-methylenetetrahydrofolate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Modufolin\u00ae", 
                    "6R-MTHF", 
                    "ISO-901", 
                    "[6R] 5,10-methylenetetrahydrofolate"
                ]
            }, 
            {
                "arm_group_label": [
                    "Levoleucovorin 200 mg/m2", 
                    "Levoleucovorin 60 mg/m2"
                ], 
                "description": "i.v. bolus injection", 
                "intervention_name": "Levoleucovorin", 
                "intervention_type": "Drug", 
                "other_name": "Isovorin\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Levoleucovorin", 
                "Leucovorin", 
                "Tetrahydrofolates"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Colon cancer", 
            "5,10-methylenetetrahydrofolate", 
            "Rectal Neoplasms", 
            "Colorectal Neoplasms", 
            "Intestinal Neoplasms", 
            "Gastrointestinal Neoplasms", 
            "Digestive System Neoplasms", 
            "Gastrointestinal Diseases", 
            "Therapeutic Uses", 
            "Pharmacokinetics", 
            "Pharmacodynamics"
        ], 
        "lastchanged_date": "March 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Gothenburg", 
                    "country": "Sweden", 
                    "zip": "461 85"
                }, 
                "name": "Sahlgrenska University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Single-blind, Randomized Phase I/II Study of Pharmacokinetic and Pharmacodynamic Investigation of Modufolin\u00ae Compared to Levoleucovorin in Tumor, Adjacent Mucosa and Plasma for Patients With Colon Cancer", 
        "overall_official": {
            "affiliation": "Sahlgrenska University Hospital, Sweden", 
            "last_name": "Kristoffer Derwinger, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Sweden: Regional Ethical Review Board", 
                "Sweden: Medical Products Agency", 
                "Sweden: Swedish Data Inspection Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Comparison of folate concentration in tumor tissue and adjacent mucosa between treatment arms.", 
            "safety_issue": "No", 
            "time_frame": "Sample taken Day 1 (Day of surgery)."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01681472"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "To explore if there is a difference in pharmacokinetic parameters of [6R] 5,10- methylene-THF, 5-formyl-THF, 5-methyl-THF and THF calculated from plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "Samples taken on Screening visit, Day 1 and Day 2."
            }, 
            {
                "measure": "To study safety in terms of adverse events and laboratory measurements; haematology, clinical chemistry and urinalysis.", 
                "safety_issue": "Yes", 
                "time_frame": "Screening visit until end of study, Day 5"
            }, 
            {
                "measure": "To study gene expression in tumor and mucosa.", 
                "safety_issue": "No", 
                "time_frame": "Sample taken Day 1 (Day of Surgery)"
            }, 
            {
                "measure": "To study homocystein and serum folate levels.", 
                "safety_issue": "No", 
                "time_frame": "Samples taken at Screening visit, Day 2 and End of Study (Day 5)"
            }
        ], 
        "source": "Isofol Medical AB", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Isofol Medical AB", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}